TNFRSF17 and plasma cell myeloma: BCMA-targeted therapies, including chimeric antigen receptor (CAR) T-cell therapies and bispecific antibodies (BsAbs), leverage T cell-mediated cytotoxicity to selectively eliminate myeloma cells and have become central to relapsed refractory MM (RRMM) treatment.